|
|
Volumn 9, Issue 2, 2003, Pages 150-158
|
|
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALENDRONIC ACID;
ANTIESTROGEN;
CALCIUM;
ESTROGEN;
GESTAGEN;
RALOXIFENE;
VITAMIN D;
AGED;
ARTICLE;
BREAST TUMOR;
COMPARATIVE STUDY;
CORONARY ARTERY DISEASE;
COST BENEFIT ANALYSIS;
DRUG COMBINATION;
ECONOMICS;
ESTROGEN THERAPY;
FEMALE;
FRACTURE;
HUMAN;
MIDDLE AGED;
POSTMENOPAUSE OSTEOPOROSIS;
RISK FACTOR;
STATISTICAL MODEL;
TIME;
AGED;
ALENDRONATE;
BREAST NEOPLASMS;
CALCIUM;
CORONARY DISEASE;
COST-BENEFIT ANALYSIS;
DRUG THERAPY, COMBINATION;
ESTROGEN ANTAGONISTS;
ESTROGEN REPLACEMENT THERAPY;
ESTROGENS;
FEMALE;
FRACTURES, BONE;
HUMANS;
MIDDLE AGED;
MODELS, ECONOMIC;
OSTEOPOROSIS, POSTMENOPAUSAL;
PROGESTINS;
RALOXIFENE;
RISK FACTORS;
TIME FACTORS;
VITAMIN D;
|
|
EID: 0142147407
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: 10.18553/jmcp.2003.9.2.150 Document Type: Article |
|
Times cited : (26)
|
|
References (0)
|
